To test this hypothesis, we evaluated the efficacy of indisulam in an immune-competent, transgenic mouse neuroblastoma model driven by MYCN and ALKF1178L (TH-MYCN/ALKF1178L) by using ultrasound imaging to quantify tumor response. Here, MYCN is linked to neoplasm.